Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing

Like
Comment
Favorite

Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing

GlobeNewswire11-14

Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Invizyne CEO Michael...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2483606863?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wkVhylWGXRT6g_x_SeNV6w--~B/aD0zMTQ7dz01NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f51d640a8d5c5b21e8b6f79eb5a4adb1","is_english":true,"pubTime":"2024-11-14 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483606863","market":"us","top_or_hot":-1,"title":"Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing","media":"GlobeNewswire","content":"<div>\n<p>Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology\n\nInvizyne CEO Michael...</p>\n\n<a href=\"https://finance.yahoo.com/news/invizyne-nasdaq-ipo-marks-era-210500244.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvizyne’s Nasdaq IPO Marks New Era of Biomanufacturing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/invizyne-nasdaq-ipo-marks-era-210500244.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology\n\nInvizyne CEO Michael...</p>\n\n<a href=\"https://finance.yahoo.com/news/invizyne-nasdaq-ipo-marks-era-210500244.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/invizyne-nasdaq-ipo-marks-era-210500244.html","article_id":"2483606863","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wkVhylWGXRT6g_x_SeNV6w--~B/aD0zMTQ7dz01NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f51d640a8d5c5b21e8b6f79eb5a4adb1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483606863","pubTimestamp":1731531900,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology. “We were frustrated with the limitations of working with enzymatic pathways inside cells, which made us wonder whether we could get rid of the cells altogether,” said Bowie. “I was lucky to have a team with enough talent and grit to actually make it work.”After founding Invizyne in 2019 and continuing their work to mature the technology, today’s public listing on Nasdaq marks another milestone. “The team is excited to show the world what cell-free biomanufacturing can do,” Bowie said. “I personally believe there is a huge potential to replace much of current chemical production with our environmentally friendly alternative.”Invizyne CEO Michael Heltzen comments on the company’s IPO","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4127":"投资银行业与经纪业","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","MDBH":"MDB Capital Holdings LLC-A","BK4585":"ETF&股票定投概念",".IXIC":"NASDAQ Composite","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股"},"translate_title":"Invizyne纳斯达克IPO标志着生物制造新时代","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"NDAQ":1,"MDBH":0.9},"content_text":"Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology\n\nInvizyne CEO Michael Heltzen comments on the company’s IPO\n\n\n\n   Invizyne CEO Michael Heltzen comments on the company’s IPO\n  \n\n\nMonrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) (\"Invizyne\"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, started trading on Nasdaq. The successful initial public offering marks the next era of biomanufacturing, based on an idea pioneered by UCLA Professor Emeritus James Bowie over a decade ago – making enzymatic pathways function outside the constraints of living cells.\n“We were frustrated with the limitations of working with enzymatic pathways inside cells, which made us wonder whether we could get rid of the cells altogether,” said Bowie. “I was lucky to have a team with enough talent and grit to actually make it work.”  \nAfter founding Invizyne in 2019 and continuing their work to mature the technology, today’s public listing on Nasdaq marks another milestone. “The team is excited to show the world what cell-free biomanufacturing can do,” Bowie said. “I personally believe there is a huge potential to replace much of current chemical production with our environmentally friendly alternative.”\nInvizyne CEO Michael Heltzen adds, “After joining as the CEO, it quickly became obvious to me that this is a world-class scientific team, able to pull off what most scientists previously thought to be impossible. Specifically, making cell-free enzymatic pathways run chemical reactions without the need of the cell. We are thereby bypassing many of the limitations associated with cell-based synthetic biology. Now we aim to show our investors and the world that our next generation enzymes and biomanufacturing platform is commercially viable through licensing deals and different types of partnerships.” \n\nInvizyne CEO Michael Heltzen comments on the company’s IPO\nAbout InvizyneInvizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals, such as Active Pharmaceutical Ingredients (APIs), biofuels, food flavors, fragrances, cosmetics, etc. Management of Invizyne believes that its biomanufacturing platform, known as SimplePath™, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. The objective for the SimplePath™ platform is to enable the efficient production of a diverse range of chemicals otherwise impossible to make, or very expensive to make. The SimplePath™ platform not only can maximize the value of these resources but also can contribute to the development of novel and renewable chemical compounds that hold the potential to open new markets and business opportunities. \nFor more information, please visit www.invizyne.com \nForward-Looking StatementsThis press release contains \"forward-looking statements.\" These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “aim”, \"expect,\" \"anticipate,\" \"should,\" \"believe,\" \"hope,\" \"target,\" \"project,\" \"goals,\" \"estimate,\" \"potential,\" \"predict,\" \"may,\" \"will,\" \"might,\" \"could,\" \"intend,\" \"shall\" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.\nForward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.\nMedia contacts:Lasse Görlitz, VP of Communications(858) 319-7135press@invizyne.com \nInvestor Relations Contact:IR@invizyne.com \n Attachment \n\n Invizyne CEO Michael Heltzen comments on the company’s IPO","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}